PMID- 31390822
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 7
IP  - 3
DP  - 2019 Aug 6
TI  - Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in 
      Kidney Transplant Recipients.
LID - 10.3390/vaccines7030084 [doi]
LID - 84
AB  - In transplant recipients vaccination against Streptococcus pneumoniae is 
      recommended to reduce mortality from invasive pneumococcal disease. It is still 
      debated if vaccination in transplant recipients triggers alloresponses. 
      Therefore, it was our aim to define if vaccination with Prevenar 13((R)), a 
      13-valent, conjugated pneumococcal vaccine (Pfizer, New York, NY, USA) that acts 
      T cell dependently, induces human leukocyte antigen (HLA) antibodies in 
      clinically stable kidney transplant recipients. Forty-seven patients were 
      vaccinated once with Prevenar 13((R)) and HLA antibodies were determined prior to 
      vaccination and at month 1 and 12 thereafter. In parallel, pneumococcal IgG 
      antibodies were measured. Using Luminex Mixed Beads technology (One 
      Lambda/Thermo Fisher, Canoga Park, CA, USA) we observed overall no change in HLA 
      antibodies after vaccination. Pneumococcal antibodies increased significantly at 
      month 1 (p < 0.0001) and remained elevated at month 12 (p < 0.005). A more 
      detailed analysis of HLA antibodies showed that in 18 females HLA class I and II 
      antibodies increased significantly at month 1 and 12 (p < 0.05); whereas in 29 
      males HLA class I and II antibodies tended to decrease. Using Luminex Single 
      Antigen Beads assay, no de novo donor-specific HLA antibodies were detected after 
      vaccination. In conclusion, the current data indicate that females may be more 
      susceptible to the induction of (non-specific) HLA antibodies after vaccination.
FAU - Lindemann, Monika
AU  - Lindemann M
AD  - Institute for Transfusion Medicine, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany. monika.lindemann@uk-essen.de.
FAU - Oesterreich, Simon
AU  - Oesterreich S
AD  - Institute for Transfusion Medicine, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany.
AD  - Department of Nephrology, University Hospital Essen, University Duisburg-Essen, 
      45147 Essen, Germany.
AD  - Department of Infectious Disease, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany.
FAU - Wilde, Benjamin
AU  - Wilde B
AD  - Department of Nephrology, University Hospital Essen, University Duisburg-Essen, 
      45147 Essen, Germany.
FAU - Eisenberger, Ute
AU  - Eisenberger U
AD  - Department of Nephrology, University Hospital Essen, University Duisburg-Essen, 
      45147 Essen, Germany.
FAU - Muelling, Nils
AU  - Muelling N
AD  - Department of Nephrology, University Hospital Essen, University Duisburg-Essen, 
      45147 Essen, Germany.
FAU - Horn, Peter A
AU  - Horn PA
AD  - Institute for Transfusion Medicine, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany.
FAU - Heinemann, Falko M
AU  - Heinemann FM
AD  - Institute for Transfusion Medicine, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany.
FAU - Witzke, Oliver
AU  - Witzke O
AD  - Department of Infectious Disease, University Hospital Essen, University 
      Duisburg-Essen, 45147 Essen, Germany.
LA  - eng
GR  - Open Access Publication Fund/University of Duisburg-Essen/
GR  - Grant to Benjamin Wilde/Werner Jackstadt-Stiftung/
PT  - Journal Article
DEP - 20190806
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC6789899
OTO - NOTNLM
OT  - HLA antibodies
OT  - Streptococcus pneumoniae
OT  - kidney transplantation
OT  - sex-specific difference
OT  - vaccination
COIS- The authors declare no conflict of interest related to the current project. 
      However, Oliver Witzke received research grants for clinical studies, speaker's 
      fees, honoraria and travel expenses from Amgen, Astellas, Bristol-Myers Squibb, 
      Chiesi, Janssen-Cilag, MSD, Novartis, Roche, Pfizer and Sanofi. He has also been 
      an investigator for Shire. Oliver Witzke is supported by an unrestricted grant of 
      the Rudolf-Ackermann-Stiftung (Stiftung fur Klinische Infektiologie).
EDAT- 2019/08/09 06:00
MHDA- 2019/08/09 06:01
PMCR- 2019/08/06
CRDT- 2019/08/09 06:00
PHST- 2019/07/11 00:00 [received]
PHST- 2019/07/30 00:00 [revised]
PHST- 2019/08/01 00:00 [accepted]
PHST- 2019/08/09 06:00 [entrez]
PHST- 2019/08/09 06:00 [pubmed]
PHST- 2019/08/09 06:01 [medline]
PHST- 2019/08/06 00:00 [pmc-release]
AID - vaccines7030084 [pii]
AID - vaccines-07-00084 [pii]
AID - 10.3390/vaccines7030084 [doi]
PST - epublish
SO  - Vaccines (Basel). 2019 Aug 6;7(3):84. doi: 10.3390/vaccines7030084.